Summary of Product Characteristics
last updated on the eMC:
21/04/2010
When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.
Updated on 21/04/2010 and displayed until Current
|
Reasons for adding or updating:
|
-
Change to section 4.4 - Special warnings and precautions for Use
-
Change to section 4.8 - Undesirable Effects
|
| Date of revision of text on the SPC: 12-Apr-2010 |
| Legal Category: POM |
| Black Triangle (CHM):
NO |
Free-text change information supplied by the pharmaceutical company
|
|
Section 4.4 Now includes the following text
Patients with coronary artery disease may be more susceptible to angina or myocardial infarction caused by ergometrine-induced vasospasm.
Section 4.8 Now includes the follwoing text
Cardiac disorders: coronary arteriospasm with very rare reports of myocardial
infarction
|
|
Updated on 28/10/2003 and displayed until 21/04/2010
|
Reasons for adding or updating:
|
-
Correction of spelling/typing errors
|
|
Updated on 03/10/2003 and displayed until 28/10/2003
|
Reasons for adding or updating:
|
-
Improved Electronic Presentation
|
|
Updated on 16/07/2001 and displayed until 03/10/2003
|
Reasons for adding or updating:
|
-
Correction of spelling/typing errors
|
|
Updated on 13/07/2001 and displayed until 16/07/2001
|
Reasons for adding or updating:
|
-
Transferred from eMC version 1
|
|
Updated on 06/09/1999 and displayed until 13/07/2001
|
Reasons for adding or updating:
|
|
|
|
